Lupin sets off Indian pharma's long road to redemption
Hit by bans and sanctions, Indian drugmakers work overtime to satisfy FDA on hygiene, safety standards
Goa
IN 28 years in India's pharmaceuticals sector, Rajiv Desai has never been busier. Most of the last six months on his desk calendar is marked green, indicating visits to the 12 plants of Lupin, India's No 2 drugmaker, where Mr Desai is a senior quality control executive. Only one day is red - a day off.
That's what is needed these days to satisfy the US Food and Drug Administration (FDA) that standards are being met. "In this sector, you're only as good as your last inspection," Mr Desai said in his office in suburban Mumbai.
Often dubbed "the pharmacy of the world", In…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO